Biotech

Theranostic radiopharmaceuticals
#Aptamer Group #Biotech #Radiopharmaceuticals

Radiopharmaceutical programme to develop therapeutic targets 

Biotechnology company Aptamer Group has launched a radiopharmaceutical programme to develop new therapeutic targets.  The programme, launched in collaboration with Radiopharmium, will look to develop three strategic therapeutic targets across high-value clinical indications.  The targets were identified through Aptamer’s Optimer platform and will now be progressed through in vitro… Read More

#News

#Biotech #Cancer research #Head and neck cancer

Outrun to develop treatment for head and neck cancer 

Biotechnology company Outrun Therapeutics has announced its lead programme for the treatment of HPV positive head and neck cancer.  The company has selected an E6AP inhibitor strategy as the lead programme from its first-in-class therapeutic pipeline, developed through its proprietary XL discovery platform. The platform has been… Read More

#Cancer Research #News

#Autoimmune disease #Biotech #Immunotherapy

Commit Biologics appoints CEO, advances therapeutics pipeline 

Biotechnology company Commit Biologics has appointed Thomas Montgomery Andresen as CEO as it aims to take its complement-powered immune engagers into clinic.  Commit described Andresen as “a serial biotech entrepreneur”, with over 20 years of experience building high-value biotech ventures at the intersection of therapeutic innovation and bioengineering.  … Read More

#News

Conference speaker
#Biotech #ELRIG #Screening

ELRIG announces keynote speakers for Gothenburg conference 

ELRIG has announced the keynote speakers for its ‘Advances in Cell-Based Screening 2026’ conference.  Professor Hazel Screen (Queen Mary University of London) and Dr Dave Powell (Relation Therapeutics) will deliver the keynote presentations during the free-to-attend event, which takes place on 6 and 7 May at AstraZeneca in Gothenburg,… Read More

#News

Cancer research in laboratory
#Antibody drug conjugate (ADC) #Biotech #Breast cancer

VALANX raises €3m to advance breast cancer ADC programme 

Biotech company VALANX Biotech has raised €3 million to advance its lead antibody-drug conjugate (ADC) programme to treat metastatic triple-negative breast cancer.  The company will use the financing for the pre-clinical development of VLX-ADC-001, a LIV-1-targeting ADC for metastatic triple-negative breast cancer (mTNBC), with candidate selection planned for June 2026.  ADCs are a… Read More

#Business & Investment #News

#Biotech #India #Peptides

Commercial peptide facility to support biotech programmes 

An expanded commercial peptide facility in India will open to support emerging biotech programmes.  CDMO Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned as client demand increases.   The first of four… Read More

#News

#AI / data analytics / healthtech / informatics #Biotech #Drug development #Investment #Market reporting

Treehill Partners: Reflections on JPM and trends for 2026  

DDW Editor Reece Armstrong speaks to Ali Pashazadeh, CEO of capital market company Treehill Partners, about how his experience of this year’s JPM reflects how the industry will move forward in 2026.   The beginning of a new year in drug discovery and development is always marked with the arrival of the JP Morgan Healthcare Conference… Read More

#Business & Investment #Exclusive Content

Back pain
#Biotech #Chronic low back pain #FDA #Persica Pharmaceuticals

Therapeutic approach could treat chronic low back pain 

A targeted therapeutic approach could effectively treat chronic low back pain (cLBP), data suggests.  The Phase Ib trial of PP353, developed by biotechnology company Persica Pharmaceuticals, demonstrated a clinically meaningful and durable reduction in pain and disability in patients with chronic low back pain and Modic Type 1 changes. Results have… Read More

#News

#AI #Biotech #Breast cancer #Clinical trial #Obesity

Why AI, obesity and breast cancer will dominate 2026

The latest episode of the DDW podcast is available to listen to below. This week, Bruno Quinney speaks to DDW Editor Reece Armstrong and Deputy Editor Diana Turner to look ahead to the world of drug discovery, pharma and biotech in 2026. They explore why AI will continue to dominate… Read More

#Featured Podcasts #Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

#Biotech #Immunology #Switzerland

TECregen appoints Dr Klaas Zuideveld as CEO 

Biotechnology company TECregen has appointed Dr Klaas Zuideveld as Chief Executive Officer.  Zuideveld will lead the company’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen immune resilience.  Zuideveld arrives with experience across large pharmaceutical companies and biotech, spanning translational strategy,… Read More

#News

#AI / data analytics / healthtech / informatics #Antibodies #Biotech #Drug discovery #GLP-1 #IPO #Mergers and acquisitions #Neuroscience

JPM 2026: Less talk and more action 

‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months.  There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step!  But questions over the robustness of the biopharma sector remain – to be expected after… Read More

#Exclusive Content

UK
#Biotech #Europe #UK #UK government

UK is Europe’s leading biotech market, BIA report shows 

The UK retained its position as Europe’s leading national biotech market in 2025, a new report finds.   The BioIndustry Association’s (BIA) report ‘UK biotech financing 2025’ shows the UK market claimed 30% of all European venture financing.  That comes despite a 13.2% year-on-year drop in venture capital investment, totalling £1.79 billion ($2.45 billion) across 58 deals. … Read More

#Business & Investment #News

Heart monitor
#Biotech #Financing #Heart failure #Italy

NanoPhoria builds on record-breaking financing round

NanoPhoria Bioscience has announced the second closing of its series A financing round, including a €15 million equity investment from the European Innovation Council (EIC) Fund. The company recently received the largest ever Series A financing round in Italian biotech history, Alongside the EIC, NanoPhoria also received financial support from… Read More

#Business & Investment #News

Lab equipment
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: Discover a powerful solution for mechanism-of-action studies

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News